Just CRISPR: Is interventional genetics for rare diseases scalable? In 2025, KJ Muldoon was the first patient to be treated for a life-threatening genetic disorder with gene editing therapy. KJ received a diagnosis of severe carbamoyl-phosphate synthetase 1 deficiency (CPS1) as a neonate, and received treatment when he was 7 months old, under Expanded Access …
Dextinction and Deliberate Extinction From the dire wolf to the screwworm, scientists are turning the tools of genetics to the elimination–and recreation–of entire nonhuman species. This webinar explores how and why genetic technologies might be used to eradicate some species and recreate others, with a focus on recent efforts and near future possibilities. The ethics …
What do researchers owe the Autistic community? with panelists Monique Botha, PhD and Tara Eicher, PhD, and moderator Ari Ne’eman, PhD Click here to register.
NC Law Review Symposium at the UNC School of Law Articles and Authors: Overview: Neuroscience and the Law John M. Conley & Rami M. Major The Brain, Neuroethics, and Bioethics Leslie C. Griffin Post-trial Access to Beneficial Investigational Neural Devices Alex Foulkes Grafton & Gabriel LázaroMuñoz Off-Label Neuroimaging Jane Campbell Moriarty The Science of the …
Knowing or Not Knowing: The Ethics of Returning Genetic Risk Information for Alzheimer’s Disease with panelists Jessica Mozersky, PhD (Washington University in St. Louis) and Ruth Ottman, PhD (Columbia University), and moderator Emily Largent, JD, RN, PhD (University of Pennsylvania) The return of genetic and biomarker information in Alzheimer’s disease (AD) research has emerged as a pressing …
ELSI Friday Forum | ELSI and the Sale of Genetic Data: The Case of 23andMe with speakers Sara Gerke, JD, Neil Richards, JD, and moderator Anya Prince, JD. Genetic and associated health data of millions are collected and held by biobanks, DTC companies, pharmacies, academic medical centers, hospitals, technology companies and other entities. These institutions are increasingly …
Biosecurity in the Age of AI and Genomics with speakers Jassi Pannu, MD, Gigi Gronvall, PhD, and moderator Stephanie Guerra, PhD. The convergence of AI and biotechnology is reshaping both the promise and the peril of biological research, potentially increasing beneficial capabilities to achieve new therapeutics faster while also introducing new risks that nefarious actors could misuse of …
Rigor, Reproducibility and Responsibility: ELSI Questions in Population Data Practices with speakers Anne Flanagin, RN, MA, FAAN, Genevieve Wojcik, PhD, MHS, and moderator Aliya Saperstein, PhD. As large-scale genomic data sets are increasingly linked, harmonized, and repurposed across studies, questions about how to meaningfully define and compare population descriptors have taken on renewed urgency. This panel brings together …
Jonathan Engel, PhD This virtual Columbia Ethics Grand Rounds took place on May 13, 2025. https://www.mhe.cuimc.columbia.edu/news/ethics-grand-rounds-great-friendship-evolution-government-university-science-partnership-united-states Resource List Bush, V. (1980). Science: The Endless Frontier. (link is external and opens in a new window)National Science Foundation. Engel, J. (2023). Transforming American Science: Universities, the Government, and the Cold War(link is external and opens in …
Tuesday, May 6 4:00—5:00pm ET Roper Hall 6310 or via Zoom Presented by Richard Sharp, Ph.D. Lloyd A. and Barbara A. Amundson Professor of Biomedical Ethics and Professor of Medicine, Mayo Clinic Director of the Biomedical Ethics Program, the Center for Individualized Medicine Bioethics Program, and the Clinical and Translational Research Ethics Program While artificial …